Oramed Selected to Present at the 81st European Atherosclerosis Society Congress in Lyon, France, June 2-5, 2013

   Oramed Selected to Present at the 81st European Atherosclerosis Society
                   Congress in Lyon, France, June 2-5, 2013

PR Newswire

JERUSALEM, June 3, 2013

JERUSALEM, June 3, 2013 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a
developer of oral drug delivery systems, announced today that its abstract,
titled "Decreased CRP levels in response to a six-week, once-daily oral
insulin regimen" has been selected for a poster presentation at the 81st
European Atherosclerosis Society (EAS) Congressbeing held on June 2-5 in
Lyon, France.

The poster will be on display from 15:30 on Sunday, June 2nd, 2013and will
remain on display until the end of sessions on Wednesday, June 5th, 2013.
Oramed's Chief Scientific Officer, Dr. Miriam Kidron, will be present to
participate in the two poster sessions taking place in the center of the
Exhibition area onMonday, June 3^rd,from12:30-15:00 and Tuesday, June 4th
from 12:30-15:00.

The poster will be available on Oramed's website, at the conclusion of the
conference, here: http://oramed.com/index.php?page=13

About The EAS

The EAS was founded in 1964 with the aim of "advancing and exchanging
knowledge concerning the causes, natural history, treatment and prevention of
atherosclerotic disease." The EAS's goal is to provide a framework for
concerted scientific and clinical discussion of new development in basic
research, diagnosis and therapy of atherosclerosis. The Society organizes
annual conferences and publishes a monthly, well-respected, peer-reviewed
journal, Atherosclerosis.

For more information on the EAS: http://www.eas-society.org/

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery
solutions for drugs and vaccines currently delivered via injection.
Established in 2006, Oramed's technology is based on over 30 years of research
by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is
seeking to revolutionize the treatment of diabetes through its proprietary
flagship product, an orally ingestible insulin capsule (ORMD-0801) currently
initiating Phase 2 clinical trials under an Investigational New Drug
application with the U.S. Food and Drug Administration, and with its oral
exenatide capsule (ORMD-0901; a GLP-1 analog), with trials on healthy
volunteers (Phase 1b) and diabetic patients (Phase 2a) underway. The company's
corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release,
please visithttp://www.oramed.com

Forward-looking statements: This press release contains forward-looking
statements. For example, we are using forward-looking statements when we
discuss revolutionizing the treatment of diabetes with our products, or when
we discuss our clinical trials. These forward-looking statements are based on
the current expectations of the management of Oramed only, and are subject to
a number of factors and uncertainties that could cause actual results to
differ materially from those described in the forward-looking statements,
including the risks and uncertainties related to the progress, timing, cost,
and results of clinical trials and product development programs; difficulties
or delays in obtaining regulatory approval or patent protection for our
product candidates; competition from other pharmaceutical or biotechnology
companies; and our ability to obtain additional funding required to conduct
our research, development and commercialization activities. In addition, the
following factors, among others, could cause actual results to differ
materially from those described in the forward-looking statements: changes in
technology and market requirements; delays or obstacles in launching our
clinical trials; changes in legislation; inability to timely develop and
introduce new technologies, products and applications; lack of validation of
our technology as we progress further and lack of acceptance of our methods by
the scientific community; inability to retain or attract key employees whose
knowledge is essential to the development of our products; unforeseen
scientific difficulties that may develop with our process; greater cost of
final product than anticipated; loss of market share and pressure on pricing
resulting from competition; laboratory results that do not translate to
equally good results in real settings; our patents may not be sufficient; and
final that products may harm recipients, all of which could cause the actual
results or performance of Oramed to differ materially from those contemplated
in such forward-looking statements. Except as otherwise required by law,
Oramed undertakes no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events. For a more
detailed description of the risks and uncertainties affecting Oramed,
reference is made to Oramed's reports filed from time to time with the
Securities and Exchange Commission.

Company Contact:
Oramed Pharmaceuticals
Aviva Sherman
Mobile: +972-54-792-4438
Office:+972-2-566-0001
Email: aviva@oramed.com

SOURCE Oramed Pharmaceuticals Inc.